Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fosmidomycin for malaria.

Michel A Missinou1, Steffen Borrmann, Andreas Schindler

  • 1Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon

Lancet (London, England)
|December 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malaria transmission dynamics, vector diversity, and insecticide resistance profiles in two health districts of southern Benin.

BMC infectious diseases·2026
Same author

Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections.

PLoS pathogens·2026
Same author

Effect of industrial palm plantation on the ecological patterns of Aedes aegypti and Culex quinquefasciatus (Diptera: Culicidae) in high arboviral risk areas, southeastern Côte d'Ivoire.

Journal of medical entomology·2026
Same author

Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIV.

Antimicrobial agents and chemotherapy·2026
Same author

[Borderline personality disorder as a severe mental illness: results of an empirical study].

Psychiatrische Praxis·2026
Same author

Risk-based selection for carotid revascularisation using the IMPROVE score versus standard care in symptomatic carotid artery disease: a model-based cost-effectiveness analysis using pooled-data.

BMJ open·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

New antimalarial drug fosmidomycin shows promise. A 4-day treatment of fosmidomycin effectively treated malaria in adults, demonstrating good tolerability and high cure rates.

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Urgent need for novel antimalarial drugs with new mechanisms of action.
  • Fosmidomycin inhibits isoprenoid synthesis in Plasmodium falciparum.
  • Fosmidomycin demonstrates efficacy against multidrug-resistant malaria strains in vitro.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of fosmidomycin in adults with malaria.
  • To determine optimal treatment duration for fosmidomycin therapy.

Main Methods:

  • Adult patients with malaria received fosmidomycin (1.2 g every 8 h) for 5, 4, or 3 days.
  • Treatment regimens were assessed for tolerability and cure rates at day 14.
  • Nine, eight, and ten patients were evaluated for 5, 4, and 3-day treatment durations, respectively.

Related Experiment Videos

Main Results:

  • All fosmidomycin treatment regimens were well tolerated by patients.
  • Day 14 cure rates were 89% (5 days), 88% (4 days), and 60% (3 days).
  • A minimum treatment duration of 4 days is suggested for optimal efficacy.

Conclusions:

  • Fosmidomycin is a safe and effective antimalarial treatment for uncomplicated malaria.
  • A 4-day treatment course of fosmidomycin achieves high cure rates.
  • Further investigation into longer treatment durations may be warranted.